I wasn't using statistics. Some basic logic is all.
In Lavender study, it is a double blind placebo study so we wont know a result until everyone is done.
The Lilac is open label study with everyone on the drug so the parents, caregivers know they are receiving the drug now.. If you spend 40 weeks on a drug and it has no visible effect that the parent of caregiver can see, then why would you continue onto a second study (Lilac 2)? If you were a parent, caregiver actively looking for a solution their are several other trials in Retts looking to enrol (albeit earlier stage but available)..
That is the simple logic I am applying here. This is my opinion only. Not investment advice and Do your own research!
new trial Trofinetide, page-18
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.50 |
Change
0.190(0.98%) |
Mkt cap ! $2.490B | |||
| Open | High | Low | Value | Volume |
| $19.39 | $19.98 | $19.38 | $7.285M | 370.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 7318 | $19.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.52 | 593 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.55 |
Change
0.190 ( 0.83 %) |
||||
| Open | High | Low | Volume | ||
| $19.41 | $19.97 | $19.39 | 83274 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| NEU (ASX) Chart |